• Home
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • Services
    • Proteomics
    • Genomics Transcriptomics
    • Flow Cytometry
    • Assay Development
    • Monoclonal Antibodies
    • Biobanking
    • Biomarker Data Analyses
    • Biomarker Regulatory Services
  • Products
    • EASYCOV
    • FIMICS
    • BIOPRED
    • IVD Products
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
    • Your Customized Kit
  • R&D
  • Quality
  • Investors
    • Financial Management
    • Financial Data
    • Shareholders
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
  • Careers
Contact
Firalis
  • Home
  • About
  • Services
  • Products
  • R&D
  • Quality
  • Investors
  • Media

Newsletters

Olink in Covid-19 R&D

Olink in Covid-19 R&D

Outstanding Olink technology offering for COVID-19 Research

06.08.2020

Biopred : Firalis innovative product

Biopred: Revolutionary approach to explore inflammatory autoimmune pathways

13.03.2020

Olink technology

Targeted protein biomarker discovery with Olink technology

08.03.2020

NextSeq 500

Identify your genomic targets with Next Generation Sequencing at Firalis

05.03.2020

Largest multiplex measurement

Accelerate your Oncology Research with the unique solution at Firalis.

04.03.2020

Ella at Firalis

Ella at Firalis for your multiparallel immunoassays

02.03.2020

Load More

Follow us on

Contact Firalis

Firalis Group

© Copyright 2020 all rights reserved. 

The company logos, products and service marks are trademarks or registered trademarks of Firalis.

-----------------------------------------------------------------------------------------------------------------------

Information addressed to health professionals. The products presented on this site are for professional use only and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

-----------------------------------------------------------------------------------------------------------------------

Headquarter : 17 Rue du Fort 68330 Huningue FRANCE

follow Firalis on
Linkedin

EasyCOV

The first Covid-19 Rapid Salivary Test

99% Specific & 86% Sensitive

 

  • No more painful NP Swabs
  • No need for a Laboratory
  • Since 22/01/2021 officially equal to an RT-PCR Test!
  • Sample to Result time only 40 Minutes!
  • Result in an instant thanks to RT-LAMP Technology

 

LEARN MORE &

GET YOUR QUOTATION NOW !

EasyCOV

The first Covid-19 Rapid Salivary Test

99% Specific & 86% Sensitive

 

  • No more painful NP Swabs
  • No need for a Laboratory
  • Since 22/01/2021 officially equal to an RT-PCR Test!
  • Sample to Result time only 40 Minutes!
  • Result in an instant thanks to RT-LAMP Technology

 

LEARN MORE &

GET YOUR QUOTATION NOW !